Table 1.
Clinical Characteristics of Patients Who Had Clozapine Treatmenta
| Characteristic | Patients | |
| Diagnosis, n (%) | ||
| Schizophrenia | 93 | (82) |
| Schizoaffective disorder | 8 | (7) |
| Psychosis not otherwise specified | 5 | (4) |
| Other diagnoses | 4 | (4) |
| Not done | 3 | (3) |
| Sex, men, n (%) | 73 | (65) |
| Age, mean ± SD (range, minimum–maximum), y | 44 ± 11 | (13–73) |
| Current smoker, n (%) | 54 | (48) |
| Body weight, mean ± SD (range, minimum–maximum), kg | 90 ± 19 | (48–166) |
| Increased waist circumference, n (%)b | 74 | (68) |
| > 102 cm (men) | 47 | (66) |
| > 88 cm (women) | 27 | (71) |
| Fasting glucose > 5.6 mmol/L, n (%)b | 55 | (52) |
| Men | 39 | (60) |
| Women | 16 | (40) |
| Antidiabetic medication, n (%) | 7 | (6) |
| Clozapine daily dose, mean ± SD (range, minimum–maximum), mg | 324 ± 160 | (50–875) |
| Concurrent drugs, n (%)c | ||
| Carbamazepine | 3 | (3) |
| Omeprazole | 3 | (3) |
| Metoprolol | 3 | (3) |
| Propranolol | 2 | (2) |
| Paroxetine | 2 | (2) |
| Fluvoxamine | 0 | (0) |
| Plasma drug levels, mean ± SD (range, minimum–maximum), nmol/L | ||
| Clozapine | 1,615 ± 1,354 | (143–8,070) |
| Norclozapine | 787 ± 528 | (100–3,110) |
a
N = 113 patients (but N for different variables was varied because of sporadic missing information).
b
Increased waist circumference and raised fasting glucose according to the global definition of the metabolic syndrome.23
c
Information available about drugs used concurrently with clozapine in 93 patients (82%).